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Abstract: Background: Despite the term acute kidney injury (AKI), clinical biomarkers for AKI
reflect function rather than injury and independent markers of injury are needed. Tubular cell death,
including necroptotic cell death, is a key feature of AKI. Cyclophilin A (CypA) is an intracellular
protein that has been reported to be released during necroptosis. We have now explored CypA as
a potential marker for kidney injury in cultured tubular cells and in clinical settings of ischemia-
reperfusion injury (IRI), characterized by limitations of current diagnostic criteria for AKI. Methods:
CypA was analyzed in cultured human and murine proximal tubular epithelial cells exposed to chem-
ical hypoxia, hypoxia/reoxygenation (H/R) or other cell death (apoptosis, necroptosis, ferroptosis)
inducers. Urinary levels of CypA (uCypA) were analyzed in patients after nephron sparing surgery
(NSS) in which the contralateral kidney is not disturbed and kidney grafts with initial function.
Results: Intracellular CypA remained unchanged while supernatant CypA increased in parallel to
cell death induction. uCypA levels were higher in NSS patients with renal artery clamping (that
is, with NSS-IRI) than in no clamping (NSS-no IRI), and in kidney transplantation (KT) recipients
(KT-IRI) even in the presence of preserved or improving kidney function, while this was not the case
for urinary Neutrophil gelatinase-associated lipocalin (NGAL). Furthermore, higher uCypA levels
in NSS patients were associated with longer surgery duration and the incidence of AKI increased
from 10% when using serum creatinine (sCr) or urinary output criteria to 36% when using high
uCypA levels in NNS clamping patients. Conclusions: CypA is released by kidney tubular cells
during different forms of cell death, and uCypA increased during IRI-induced clinical kidney injury
independently from kidney function parameters. Thus, uCypA is a potential biomarker of kidney
injury, which is independent from decreased kidney function.
Keywords: acute kidney injury; tubular cell death; kidney transplantation; kidney cancer; ischemia-
reperfusion
1. Introduction
Acute kidney injury (AKI) is a multifactorial and multiphasic kidney disease charac-
terized by a rapid decline in kidney function, resulting in the accumulation of metabolic
waste and toxins [1]. The main causes of parenchymal AKI include ischemia-reperfusion
injury (IRI) and endogenous, as well as exogenous, nephrotoxins. Notwithstanding ad-
vances in preventive strategies and support measures, AKI continues to be associated
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with high morbidity and mortality. Despite its name, which includes the term “injury”
rather than “failure”, current diagnostic criteria for AKI rely on evidence of decreased
kidney function and not on evidence of kidney injury [1]. Decreased urine output or
increased serum creatinine (sCr) may be observed in functional situations in the absence of
kidney injury. As examples, sCr may increase, due to functional reasons, in the absence of
injury when drugs that decrease the tubular secretion of creatinine are prescribed or when
nephroprotective drugs decrease hyperfiltration, without concomitant kidney injury. Thus,
biomarkers of actual kidney damage (injury) are needed for early diagnosis (before kidney
function decreases), differential diagnosis (injury versus functional changes in the absence
of injury) and the staging (e.g., is injury ongoing or not) of kidney injury that allows for
early intervention and the adequate selection of therapeutic agents to improve outcomes.
Tubular cell death is a hallmark of parenchymal AKI [2–5]. Both apoptosis and
regulated necrosis (RN) may contribute to tubular cell death and may be modulated
therapeutically [4,5]. RN pathways include necroptosis, ferroptosis, mitochondria perme-
ability transition-regulated necrosis, and pyroptosis, the later been a form of cell death in
macrophages [3]. Tubular cell death is usually an early event during AKI that is followed by
tubular regeneration. However, RN may trigger kidney inflammation that drives a second
wave of tubular cell death, that contributes to maintaining decreased kidney function [6].
Indeed, we recently identified necroptosis as a key mode of cell death in experimental AKI
and set out to explore potential biomarkers of necroptosis in the clinical setting. For that
we identified a clinical scenario in which a highly controlled ischemia injury to the kidney
occurred and in which traditional methods to assess kidney injury (based on functional
changes) may not be informative, i.e., a clinical setting in which information provided by a
marker of injury (rather than of function) may be clinically relevant.
Elective surgical aggression to the kidney, such as nephron sparing surgery (NSS) with
renal artery clamping and tumor resection, or kidney transplantation (KT) with anoxia,
hypothermia and reperfusion represent clinical practice models of kidney IRI that may or
may not result in clinical AKI as per the current consensus definition based on functional
assessment [7]. Thus, in NSS, the contralateral kidney is not disturbed and may provide
sufficient urine volume or glomerular filtration rate (GFR) to limit or prevent a decrease
in diuresis or increase in sCr, despite histological tubular necrosis related to ischemia,
and thus, patients may not fulfill current (functional) criteria to diagnose AKI. In KT,
despite ischemic injury to the graft, the injured graft may still provide better GFR that
the non-functioning native kidneys, and diuresis and decreasing sCr may be observed
in the presence of histological kidney injury, unless the graft injury is severe, leading
to primary non-function. The ability to assess AKI by noninvasive tools before kidney
function declines, with the accurate categorization of severity and the possibility to identify
different causes may improve the functional outcome after kidney surgery.
Cyclophilin A (CypA) is the most abundant and ubiquitous member of the cyclophilin
family of four proteins (A, B, C, and D) [8,9]. CypA is an 18 kDa intracellular protein with
roles in protein folding, trafficking, and T-cell activation [8,10–12]. CypA has been reported
to be actively released to the extracellular milieu by injured cells and extracellular CypA
could activate inflammation and proliferation [13]. Specifically, cytosolic CypA is released
early in necroptosis, and has been proposed to be a biomarker for this type of cell death
when the integrity of the plasma membrane is compromised [14]. High levels of CypA are
found in the kidney [15,16]. Stressed proximal tubular cells release CypA; however, the
relationship of this release to tubular cell death was not previously studied. In this regard,
urinary CypA (uCypA) was reported to be increased in diabetic kidney disease, a condition
associated with tubular cell death, increased glomerular permeability and proximal tubular
dysfunction [17,18]. CypA can be freely filtered by kidney glomeruli; therefore, higher
levels in urine samples may reflect an increase in serum levels or elevated excretion by
injured kidney tubular cells. In this regard, both serum and urine CypA were higher in
patients with postoperative AKI after cardiac surgery and, thus, increased serum CypA
appears to be a biomarker of deceased kidney function [19].
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Thus, we set out to explore whether uCypA could be a marker of tubular cell necrop-
tosis in the clinic. Now, we report that CypA is released by proximal tubular kidney
cells exposed to different lethal stimuli that induce diverse forms of cell death. Moreover,
uCypA increased in clinical situations of kidney injury even when there was no associated
functional impairment and it better associated with clinical evidence of more severe kid-
ney insult than the more classical biomarker NGAL. We, therefore, identify uCypA as a
potential biomarker of kidney injury independent from reduced kidney function.
2. Materials and Methods
2.1. Cell Culture
Two tubular cell lines were studied, human (HK-2) [20] and murine (MCT) [21]
immortalized proximal tubular epithelial cell lines. HK-2 cells were grown in RPMI 1640
(Thermo Fisher, Waltham, MA, USA), 10% decomplemented fetal bovine serum (FBS)
(Sigma-Aldrich-Merck KGaA, Damstadt, Germany), 1% glutamine, 100 U/mL penicillin,
100 µg/mL streptomycin, 5 µg/mL Insulin Transferrin Selenium (ITS) and 36 ng/mL
hydrocortisone in 5% CO2 at 37 ◦C. MCTs were grown in RPMI 1640, 10% FBS, 100 µg/mL
streptomycin, 2 mM glutamine, and 100 U/mL penicillin. At 60–70% of confluence, cells
were growth-arrested in serum-free medium for 24 h before the experiments.
HK2 were exposed to the chemical hypoxia inducer CoCl2 (Merck, Darmstadt, Ger-
many) at 500 µM and to the ferroptosis inducer RSL3 (SelleckChem, Houston, TX, USA)
at 400 nM. MCT cells were exposed to lethal cytokine cocktail that induces apoptosis
(TTI), consisting of 100 ng/mL TWEAK (Merck), 30 ng/mL TNFα (PeproTech, Rocky Hill,
NJ, USA) and 30 U/mL interferonγ (PeproTech, Rocky Hill, NJ, USA), to which 25 µM
pan-caspase inhibitor carbobenzoxy-valyl-alanyl-aspartyl-[O-methyl]-fluoromethylketone
(TTI+zVAD) (Bachem, Bubendorf, Switzerland) may be added to switch the mode of cell
death to necroptosis [6,22]. To perform hypoxia/reoxygenation (H/R) experiments, MCT
cells were cultured for 24 h in a hypoxic atmosphere containing 1% O2, 94% N2, 5% CO2
(Air Liquide, Madrid, Spain) in serum-free RPMI medium, after cells were maintained in
21% O2 for reoxygenation for indicated periods of time [23].
2.2. Western Blot
After the removal of cell culture media, cells were trypsinized, collected and homoge-
nized in lysis buffer (50 mM TrisHCl, 150 mM NaCl, 2 mM EDTA, 2 mM EGTA, 0.2% Triton
X-100, 0.3% NP-40, 1 mM PMSF and 1 µg/mL pepstatin A) [24]. Protein concentration
was measured with the BCA (bicinchoninic acid) assay (Thermo Fisher, Waltham, MA,
USA). Cell supernatants were centrifuged at 2500 rpm, for 20 min at 4 ◦C to remove cells
and debris, and then stored at −80 ◦C until analysis. Equal amounts of protein were
loaded in 15% SDS gels, separated by electrophoresis and transferred to PVDF membranes
(polyvinylidene difluoride, Millipore, Darmstadt, Germany). The membranes were blocked
with 5% TBS/0.5% v/v Tween-20 skim milk and incubated with anti-cyclophilin A (1:500,
Abcam) and anti-HIF-1α (1:2000, Abcam) antibodies dissolved in 5% milk TBS/Tween
for 1 h at room temperature. They were then washed with TBS/Tween and incubated
with the secondary antibodies against rabbit IgG (1:5000) or mouse IgG (1:5000) from GE
Healthcare. After washing with TBS/Tween, blots were developed with the chemilumi-
nescence method (ECL; Fisher Scientific, Waltham, MA, USA) and probed with mouse
monoclonal anti-α-tubulin antibody (1:10,000; Sigma-Aldrich KGaA, Damstadt, Germany)
for HIF membranes or anti-GAPDH (1:5000, Sigma-Aldrich) for CypA membranes, as
these markers were allowed to run the gels to optimally separate the bands, given the
different molecular weights of the proteins. Levels of expression were corrected for minor
differences in loading. Cell supernatants were corrected with red ponceau staining.
2.3. Cell Viability Assay
Cell viability was estimated using the 3-[4,5-dimethylthiazol-2-yI]-2,5 diphenyltetra-
zolium bromide (MTT, Sigma Aldrich-Merck KGaA, Damstadt, Germany) colorimetric
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assay. Following stimulation, culture medium was removed, and cells were incubated with
0.5 mg/mL MTT in PBS for 1 h at 37 ◦C. The resulting formazan crystals were dried and
dissolved in DMSO. Absorbance (indicative of cell viability) was measured at 570 nm.
2.4. NSS and KT Patients
This observational study prospectively collected urinary samples and clinical data at
the Fundación Jiménez Díaz University Hospital biobank between March 2014 and June
2019. The IIS-FJD institutional review board approved the study and patients signed and
informed consent, approval date: 20 February 2019 A total of 64 patients were studied:
52 patients with a localized kidney tumor to whom a laparoscopic NSS was proposed
and 6 donor-recipient pairs of living KT patients (laparoscopic living donor nephrectomy
and conventional KT). Patients were retrospectively divided into 3 groups: laparoscopic
NSS patients without (n = 13) or with (n = 39) arterial clamping during the procedure,
and transplant (n = 6) patients with end-stage kidney disease who received a KT after
laparoscopic nephrectomy of a living related donor.
NSS patients had a healthy contralateral kidney. Medical background, tumor char-
acteristics, surgical findings, warm ischemia time (WIT) when applied and postoperative
evolution were recorded. Minimally invasive NSS involves laparoscopic approach and
arterial control with a tourniquet. The final decision on clamping the renal artery was made
by the surgeon according to the surgical situation (tumor limit visualization, bleeding or
expected WIT). Diuretics, such as furosemide and mannitol, were not used.
Kidney donor candidates were studied according to local protocols and donated the
left kidney. Kidneys were retrieved for transplantation by a laparoscopic hand-assisted
approach. WIT and cold ischemia time (CIT) were recorded.
Basal analytical data were obtained from preoperative blood testing. Postoperative
lab tests were obtained from routine clinical lab testing during hospitalization. The last
blood test available was also recorded during follow up. Urine samples were obtained
serially: before surgery, upon bladder catherization at the time of anesthesia induction
(baseline determination, Pre-Qx), immediately after surgery, before patients were woken
up from anesthesia (0 h determination), the day after surgery (24 h) and daily thereafter
(48 h, 72 h) up to 72 h while they were hospitalized.
2.5. Urine Samples Collection and ELISA
Urine samples were collected in sterile containers and centrifuged at 2500 rpm for
20 min at 4 ◦C to remove cells and debris. Supernatants were stored at −80 ◦C until
analysis. uCypA and urinary NGAL (uNGAL) were measured by an enzyme linked
immunosorbent assay (ELISA, MyBiosource, San Diego, CA, USA and Bioporto, Hellerup,
Denmark, respectively), according to the manufacturer specification. uCypA and uNGAL
were adjusted to urine creatinine levels and expressed per mg of urinary creatinine, as is
routinely done for other urinary analysis, such as albuminuria and proteinuria to account
for potential physiological differences in urine dilution.
2.6. Statistics
Results are expressed as mean ± SD in cultured cells and as mean ± SEM or median
(interquartile range) for patient data. Differences between groups were evaluated using
one-way ANOVA with Tukey’s post hoc tests using the Prism software (Graphpad 7.04).
For pairs of samples, data were analyzed using Student’s t test. Differences between
non-clamping and clamping NSS patients were assessed by Student´s t test for normally
distributed variables or by Wilcoxon rank test for non-normally distributed variables. Dif-
ferences between categorical values were assessed by Fisher’s exact test. A p-value < 0.05
was considered statistically significant.
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3. Results
3.1. Lethal Stimuli Promote CypA Release from Cultured Kidney Tubular Cells
Tubular cells represent that largest cell mass in the kidney and are key targets in
parenchymal AKI during IRI. We focused on proximal tubular cells for cell culture studies
to assess CypA release to cell culture media following exposure to lethal stimuli. Lethal
stimuli were tested in cultured human or murine cells according to their sensitivity to
specific modes of death.
Hypoxic conditions were simulated by the exposure of human proximal tubular
cells (HK-2) to 500 µM CoCl2 for different periods of time. CoCl2 decreased cell viabil-
ity (Figure 1A) and increased the hypoxia marker HIF-1α, as assessed by Western blot
(Figure 1B) in a time-dependent manner. Under these conditions, CypA released into the
cell culture media increased in a time-dependent manner, in parallel to the decreased cell vi-
ability (Figure 1C), while intracellular levels of CypA in adherent cells remained unchanged
(Figure 1D). Murine proximal tubular cells (MCT cells) were exposed to H/R resulting in a
time-dependent decreased cell viability, as confirmed by MTT assay (Figure 2A), which
was paralleled by a progressive increase in extracellular CypA (Figure 2B), again without
changes in intracellular CypA (Figure 2C).
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Figure 1. CypA is released by cultured human proximal tubular HK2 cells under chemical hypoxia.
HK2 cells were exposed to 500 µM CoCl2 for the indicated periods of time. (A) Cell viability was
assessed by the MTT assay. (B) HIF-1α expression, a marker of hypoxia, was assessed by Western blot.
(C,D) Western blot of CypA in cell super atant (C) and in cellular extracts (D). Qu ntification and
representative image. (A,C,D) Mean ± SD of thre i dependent xperim ts. * p < 0.05; ** p < 0.01;
*** p < 0.001. Uncropped gel sca s shown in Figure S1A.
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Figure 2. CypA is released by cultured murine proximal tubular MCT cells under hy-
poxia/reoxygenation. MCT cells were cultured for 24 h in a hypoxic atmosp ere, and then cells
were reoxygenated for the indicated periods of time (A) Cell viability was assessed by the MTT
assay. Mean ± SD of three independent experiments. *** p < 0.001 vs. normoxia 8 h; ### p < 0.001
vs. normoxia 24 h. (B,C) Western blot of CypA in cell supernatants (B) and in cellular extracts (C).
Quantification and representative image. Mean ± SD of three independent experiments. * p < 0.05;
** p < 0.01. Uncropped gel scans shown in Figure S1B.
To address whether CypA release is linked to any specific pathways of cell death,
tubular cells were exposed to specific inducers of different cell death pathways. Ferroptosis
was induced in HK-2 by exposure to RSL3, which resulted in decreased cell viability by
24 h, as tested by the MTT assay (Figure 3A). RSL3 also increased CypA release to the cell
culture media (Figure 3B), without changes in intracellular CypA (Figure 3C). Apoptosis
and necroptosis were induced in MCT cells by exposure to TTI and TTI/zVAD, respectively.
Both stimuli reduced cell viability (Figure 4A), and increased CypA release (Figure 4B),
without changes in intracellular CypA (Figure 4C). However, the temporal pattern of CypA
release differed between apoptosis and necroptosis, as expected from the specific character-
istics of each form of cell death [22]. Thus, as other forms of RN, necroptosis is characterized
by loss of cell membrane integrity and release of intracellular contents, and this was consis-
tent with an earlier release of CypA (Figure 4B). By contrast, apoptotic cells do not initially
release cellular contents, but in culture they are not engulfed by macrophages or adjacent
uninjured cells, and eventually the plasma membrane becomes permeabilized.
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Figure 3. Ferroptosis leads to CypA release in human proximal tubular HK2 cells. (A) HK2 cells were
exposed to 400 nM RSL3, a ferroptosis inducer, for 24 h and cell viability was assessed by the MTT
assay. Mean ± SD of three independent experiments. *** p < 0.001. (B,C) HK2 cells were exposed
to 400 nM RSL3 for indicated periods of times and CypA was measured by Western blot in cellular
supernatants (B) and in cellular extracts (C). Quantification and representative image. Mean ± SD of
three independent experiments. * p < 0.05. Uncropped gel scans shown in Figur S2A.
Overall, these results suggest that CypA is released by kidney tubular cells exposed to
lethal stimuli and CypA release is independent of the mechanism of cell death.
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Figure 4. MCT cells were exposed to the apoptosis inducer cytokine cocktail
TWEAK/TNFα/interferon-γ (TTI) or to the necroptosis inducer TTI/zVAD for the indi-
c ted periods of time. (A) Cell viability was assessed by the MTT assay. Mea ± SD of three
independent experiments. *** p < 0.001 vs. co trol. (B,C) Western blot of CypA in c ll supernatants
(B) and in cellular extracts (C). Note than controls ar in the middle of th gel and the time course is
represented from there, i.e., later time points for both stimuli are at opposite sites of the gel and
figure. Quantification and representative image. Mean ± SD of three independent experiments.
** p < 0.01 vs. control. Uncropped gel scans shown in Figure S2B.
3.2. Clinical Study: Patient Characteristics
The clinical study was performed in two different clinical settings, both characterized
by limitations in the cu rent KDIGO definition of AKI to identity kidney injury: 52 patients
undergoing N S (13 with no-clamping and 39 with clamping of renal artery) and 6 living
donor-kidney transplant recipient pairs.
Among NSS ati le 1), no significant differ nces were found between patients
wi h or without renal artery clamping re arding a e, gender, body mass index, cardio-
vascular risk factors, cardiovascular events, kidney functio or the nephromet ic scores
RENAL, P DUA, C. Index, ABC, RPS, or Mayo (Supplementary Table S1). However, tumor
size (22.5 ± 8.93 mm vs. 31.3 ± 8.93 mm, p = 0.006), DAP (5 (2.00) vs. 6 ( . ), p = 0.021) and
NePhRO (6 (2.00) vs. 8 (2.00), p = 0.011) scores were higher in t e NSS patients with renal
artery clamping. The WIT in NSS patients with arterial clamping was 23.83 ± 8.38 min.
Table 2 summarizes the characteristics of 6 pairs of KT donors and recipients. Donor
laparoscopic hand-assisted left nephrectomy was followed by uneventful graft transplanta-
tion in the right iliac fossa, immediate diuresis and no need for postoperative dialysis.
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Table 1. Characteristics of NSS patients without and with arterial clamping.
NSS without
Arterial Clamp (n = 13)
NSS with
Arterial Clamp (n = 39) p Value
Age (years, mean ± SD) 65.50 ± 8.97 60.30 ± 11.50 0.155
Female sex 5 (38.4%) 10 (25%) 0.278
Right kidney tumor 4 (30.7%) 19 (48.7%) 0.235
Tumor size * (mm, mean ± SD) 22.5 ± 8.93 31.3 ± 8.93 0.006
Nephrometric scores
RENAL (median (IQR)) [25] 6 (1.00) 6 (2.00) 0.521
PADUA (median (IQR)) [26] 7 (0.00) 8 (2.00) 0.071
C.INDEX (mean ± SD) [27] 3.25 ± 1.47 2.52 ± 0.92 0.141
DAP (median (IQR)) [28] 5 (2.00) 6 (2.00) 0.021
NePhRO (median (IQR)) [29] 6 (2.00) 8 (2.00) 0.011
ABC category [30]
1 5 (38.4%) 8 (20.5%) 0.124
2 7 (53.8%) 23 (58.9%)
3H 1 (7.6%) 2 (5.1%)
3S 0 6 (15,3%)
RPS [31] <50% 3 (23%) 7 (17.9%) 1.000
Mayo score (median (IQR) [32] 3 (2.00) 3 (3.00) 0.468
Ischemia time WIT
(min, mean ± SD) 0 23.83 ± 8.38
KDIGO criteria for AKI 1 (7.69%) 4 (10.25%) 0.613
* Maximum diameter measured by CT scan. To see full characteristics of NSS patients see Supplementary Table S1.
Table 2. Characteristics of KT patients without and with arterial clamping.
Kidney Donors (n = 6) Kidney Recipients (n = 6)
Age (years) 58.83 ± 5.91 54.00 ± 20.43
Female sex 4 (66.6%) 3 (50%)
Renal ischemia
CIT (min) 83.50 ± 7.60
WIT (min) 3.17 ± 1.27
CIT: cold ischemia time. WIT: warm ischemia time. To see full characteristics of KT patients see Supplementary
Table S2.
3.3. Renal Artery Clamping during NSS Is Associated with Increased uCypA
Among NSS patients, five met the increased sCr KDIGO diagnostic criterion for AKI
stage I after surgery, 4 (10.25%) in the clamping group and 1 (7.69%) in the non-clamping
group (p ns) (Table 1, Figure 5A).
Next, we measured uCypA levels and stratified NSS patients according to renal
artery clamping, which represents a kidney IRI. uCypA levels did not significantly change
over time in non-clamping patients and did not increase above baseline in the single
non-clamping patient that fulfilled AKI KDIGO criteria. By contrast, uCypA was already
increased immediately after surgery (uCypA values were between 14-fold and 33-fold
higher than baseline in three patients at this point) in some clamping patients and mean
values further increased up to 48 h after surgery, at which point they were significantly
higher than at baseline (10.58 ± 3.38 vs. 0.39 ± 0.08 ng/mg, p < 0.001) (Figure 5B). Individ-
ual clamping patients usually showed peak uCypA levels at 24–48 h, while no clear peak
was observed in non-clamping patients (Figure 5C). uCypA increased from baseline in the
four clamping patients who fulfilled the KDIGO AKI sCr criterion and, additionally in
15 further patients for whom increased uCypA provided evidence of kidney injury in the
absence of clinically relevant decrease in kidney function, as assessed by sCr levels. The
low sensitivity of KDIGO AKI criteria to detect AKI in this clinical setting was expected,
given that the contralateral kidney was not disturbed by surgery.
Biomedicines 2021, 9, 217 10 of 20
Biomedicines 2021, 9, x FOR PEER REVIEW 10 of 20 
 
sensitivity of KDIGO AKI criteria to detect AKI in this clinical setting was expected, given 
that the contralateral kidney was not disturbed by surgery. 
 
Figure 5. uCypA levels are increased in NSS patients with renal artery clamping but not in pa-
tients without clamping. (A) sCr levels after surgery did not differ between clamping and non-
clamping patients. (B) uCypA levels are increased after surgery in NSS patients with clamping. 
Bars represent mean ± SEM. * p < 0.05; *** p < 0.001. (C) Time course of uCypA levels in individual 
patients shows a peak at 24–48 h after surgery in most clamping patients, while no clear peak was 
observed in non-clamping patients. (B,C) uCypA is expressed as urinary CypA: urinary creatinine 
ratio. 
To gain insight into potential cut-off points of uCypA that may be used to define the 
occurrence of kidney injury, post-surgery uCypA values were compared to two different 
cut-off points. Clamping resulted in a higher percentage of patients above both cut-off 
points (Figure 6A,B). First, the cut-off point for uCypA was defined as post-surgery values 
above the highest pre-surgery uCypA value found in the study population. This uCypA 
cut-off point was labeled as an increase above baseline value (>2.5 ng/mg, Figure 6A). 
Using this definition, an immediate increase in uCypA values was observed in 26 % of 
clamping patients but in none of the no-clamping patients (Figure 6A). However, by 24 h, 
increased uCypA was observed in 31 % and 46 % of clamping and no-clamping patients 
and this difference was not statistically significant. By 48 h, uCypA values above the base-
line value cut-off point were observed almost exclusively in clamping patients (49 %). 
However, 24-h findings suggested that surgery-associated tissue injury, unrelated to kid-
ney IRI, could result in mild increases in uCypA in the early post-surgery period. Thus, a 
second uCypA cut-off point was defined as post-surgery values above the highest uCypA 
values obtained within 72 h of surgery without clamping, this was named the maximum 
injury value cut-off point (i.e., >10 ng/mg, Figure 6B) and accounted for non-specific sur-
gery-induced tissue injury, unrelated to IRI. Using this definition, only clamping resulted 
in uCypA values above the cut-off point and the percentage of patients with significant 
i ti ts it re al artery cla ping but not in patients
without clamping. (A) sCr levels after surgery did not iffer between clamping and non-clamping
patients. (B) uCypA levels are increased after surgery in NSS patients with clamping. Bars represent
mean ± SEM. * p < 0.05; *** p < 0.001. (C) Time course of uCypA levels in individual patients shows
a peak at 24–48 h after surgery in most clamping patients, while no clear peak was observed in
non-clamping patients. (B,C) uCypA is expressed as urinary CypA: urinary creatinine ratio.
To gain insight into potential cut-off points of uCypA that may be used to define the
occurrence of kidney injury, post-surgery uCypA values were compared to two different
cut-off points. Clamping resulted in a higher percentage of patients above both cut-off
points (Figure 6A,B). First, the cut-off point for uCypA was defined as post-surgery values
above the highest pre-surgery uCypA value found in the study population. This uCypA
cut-off point was labeled as an increase above baseline value (>2.5 ng/mg, Figure 6A).
Using this definition, an immediate increase in uCypA values was observed in 26% of
clamping patients but in none of the no-clamping patients (Figure 6A). However, by 24 h,
increased uCypA was observed in 31% and 46% of clamping and no-clamping patients and
this difference was not statistically significant. By 48 h, uCypA values above the baseline
value cut-off point were observed almost exclusively in clamping patients (49%). However,
24-h findings suggested that surgery-associated tissue injury, unrelated to kidney IRI,
could result in mild increases in uCypA in the early post-surgery period. Thus, a second
uCypA cut-off point was defined as post-surgery values above the highest uCypA values
obtained within 72 h of surgery without clamping, this was named the maximum injury
value cut-off point (i.e., >10 ng/mg, Figure 6B) and accounted for non-specific surgery-
i duced tissue injury, unrelated to IRI. Usin this defi ition, o ly clampi g resulted in
uCypA values above the cut-off point and the percentage of patients with significant kidn y
i j ry otentially linked to IRI increased from 8% immediately post-surgery to 28% at
48 h (Figure 6B). A total of 14 (36%) patients had a higher uCypA at some point after
surgery. Moreover, patients with uCypA above the maximum injury cut-off point showed
longer surgery duration, and higher surgical bleeding and increase in sCr after surgery
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(Figure 6C), suggesting that high levels of CypA are related to more severe kidney injury.
In this regard, the four clamping patients with clinical AKI had uCypA above baseline
value cut-off point and three of them went above the maximum injury cut-off point.
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Figure 6. Percentage of patients with high uCypA levels after NSS using two different uCypA cut-off
levels to define “high uCypA”. (A) Percentage of patients with post-surgery uCypA values above
the highest pre-surgery uCypA value, found in the study population, i.e., >25 ng/mg; *** p < 0.001.
(B) Percentage of patients with post-surgery uCypA values above the highest post-surgery uCypA
values obtained in NSS without clamping, i.e., >100 ng/mg; ** p < 0.01, *** p < 0.001. (C) Time of
surgery, surgical bleeding and increase in sCr are higher in clamping patients with CypA above
maximum injury levels. Data are presented as box plots that show the mean, 25/75 percentiles (box),
and 10/90 percentiles (bars). * p < 0.05.
Overall, these findings suggest the potential usefulness of uCypA to detect IRI kidney
injury when function parameters are unreliable.
3.4. Urine NGAL in NSS Patients
Next, we assessed a conventional kidney injury biomarker, uNGAL, in NSS patients.
Among the five NSS patients meeting the increased sCr KDIGO diagnostic criterion for
AKI stage I after surgery, only one (20%), belonging to the clamping group, had an increase
in uNGAL above baseline.
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As for uCypA, clamping resulted in numerically higher mean uNGAL values at 48 h
when compared to baseline (392 ± 81 vs. 187 ± 66 pg/mg) than in non-clamping compared
to baseline (167 ± 82 vs. 174 ± 32 pg/mg); however, these differences were not statistically
significant (Figure 7A). Indeed, the fold-change over the mean baseline values was lower
for uNGAL than for uCypA and no statistically significant differences were observed
in uNGAL in either clamping or no-clamping patients (Figure 7B). This differs from the
significant (48 h p < 0.001) and sustained mean 6.4- to 26.5-fold increase in uCypA versus
pre-surgery values in clamping patients (Figure 7B).
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pr -surgery uNGAL value found in the study population, i.e., >16 pg/mg. (D) P rcentage of patients
with post-surgery uNGAL values above the highest post-surgery uNGAL values obtained in NSS
without clamping, ** p < 0.01, *** < 0.001.
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Use of the same definitions (increase above baseline cut-off and maximum injury
cut-off values) for high uNGAL levels as previously used for uCypA did not disclose
a clear association of high uNGAL levels with either surgery or clamping for any of
the definitions (Figure 7C). While using the above maximum injury cut-off (i.e., above
peak post-surgery value in non-clamping cut-off value) resulted in a significantly higher
percentage of clamping patients with high uNGAL levels, this percentage (12.5%) was in
the range observed at baseline for both clamping and non-clamping patients (Figure 7D).
Finally, contrary to uCypA, there was no clear association between uNGAL values above
the maximum injury cut-off point with surgery duration or increased sCr after surgery
(Figure S3).
The correlation between uCypA and uNGAL was poor and only statistically significant
for clamping patients (Figure S4). Overall, these results suggest that uNGAL appears less
sensitive than uCypA to detect IRI-induced kidney injury.
3.5. Urine CypA Levels Following Living Donor KT
We next analyzed uCypA in KT patients after living kidney donation with immediate
diuresis and kidney function and progressive normalization of sCr in recipients (Figure 8A).
Mean uCypA levels in transplanted patients increased progressively from time zero as
compared with donor urine, reaching statistical significance at 48 and 72 h (Figure 8B,C).
In contrast, peak uNGAL was observed at time zero, the only time point in which it was
significantly higher than in donor urine, and uNGAL decreased thereafter (Figure 8D,E).
In this regard, pre-surgery uNGAL values in KT recipients were above those in donors
and in the range found in recipient urine at time zero, suggesting that part of this uNGAL
originated from the recipient kidneys. This is not surprising, since CKD has been associated
with increased uNGAL [33].
Overall, these results further support the potential usefulness of uCypA to detect IRI
kidney injury when function parameters are unreliable.
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4. Discussion
The main findings are that CypA is released by dying tubular cells and the release is
not specific for any form of cell death (apoptosis, necroptosis, ferroptosis), thus, potentially
identifying the ongoing kidney injury of diverse etiology. In this regard, using clinical
situations in which sCr or diuresis do not adequately represent underlying IRI-induced
kidney injury, we have identified uCypA as a marker of clinical IRI kidney injury more
sensitive that the classical markers uNGAL or sCr to detect unilateral kidney injury in
presence of a functional contralateral kidney or when kidney injury nonetheless results in
better kidney function than in the baseline situation, as is the case for KT (Figure 9). While
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these clinical situations allowed us to identify the role of uCypA as a marker of kidney
injury, it is likely that uCypA also provides similar information in other clinical situations.
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Figure 9. Conceptual figure: current issues in AKI diagnosis and contribution of uCypA. (A) Current
AKI diagnosis. (B) sCr may increase due to functional reasons, in the absence of injury. (C) Unilateral
IRI resulting from clamping of renal artery in NSS. Increased uCypA in IRI kidney injury. uCypA
was a more sensitive marker of IRI-induced kidney injury than sCr or classical markers of injury
such as NGAL. (D) In NSS without clamping, there is no IRI. (E) In KT patients, kidney graft IRI is
usually associated with decreasing sCr levels. Increased uCypA in IRI kidney injury. Again, uCypA
provided evidence of kidney injury despite decreasing sCr and non-informative uNGAL.
Currently, the diagnosis of AKI is based on indicators of kidney function, including
sCr and urine output [34]. However, kidney injury can occur in the absence of an increase
in sCr, which represents an emerging condition, called subclinical AKI, an early step in
the spectrum of kidney injury [35]. However, no injury biomarker is currently in clinical
use, and there is an unmet medical need. NGAL is one of the best characterized AKI
biomarkers. It is a 25 kDa protein expressed by ma y cells and s secret d n the kidney by
dist l tubula cells in response to ischemic or toxic injury [36], in a “s verity-dep nd nt”
anner. uNGAL may increase from 3 h after the tubular insult, peaking at 6 to 12 h
depending on the intensity of the insult [34,37]. Clinical studies have presented NGAL as
a biomarker to predict AKI, and for early diagnosis, duration and short- and long-term
outcome predictors and recovery predictors [34]. Specifically, uNGAL has been proposed as
a suitable biomarker for early detection of AKI in patients undergoing cardiac surgery [19].
However, the diagnostic cut-off values for urinary or plasma NGAL are yet unclear [38].
CypA is an abundant intracellular protein expressed by numerous tissues that could
be released by different cell types in response to diverse stimuli. In fact, the release of
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CypA has been observed in vascular smooth muscle cells (VSMCs) in response to oxidative
stress and rapamycin, in macrophages treated with LPS or high glucose, in myocytes
in response to hypoxia/reoxygenation and in activated platelets [39–43]. The cellular
mechanism that induced CypA release seems to be associated to cell death, but whether
it may represent specific forms of cell death is unclear. In Jurkat cells, CypA release was
reported as a marker of necroptosis [14], an observation that triggered the present research.
More recently, it was also linked to apoptosis in VSMCs [40]. The kidney has relatively
high levels of CypA, especially in proximal tubule epithelial cells [15,16] and we now
report that CypA is released by tubular cells in response to hypoxia and different lethal
stimuli, but it does not seem to be specific of a unique cell death pathway. Recently, it was
described that tubular cells release other proteins when exposed to cell death inducers,
such as HMGB1 and IL-33 [44,45], but their clinical relevance is unknown. The cellular
processes that mediate CypA release are unclear and may depend on the stimulus, as
observed for VSMCs, and differ for sublethal or lethal stimuli [39,40]. Our experiments
also suggest that CypA release is dependent of the loss of membrane integrity since it
was not observed at early time points during apoptosis induced by TTI. In this regard, we
hypothesize that intracellular CypA levels remained constant while extracellular CypA
levels increased because of the presence of two-cell populations; cells that remain alive
and attached to the plate, which do not release CypA and, thus, intracellular CypA levels
remain stable, and dying cells that detach from the plate and release CypA.
CypA can be freely filtered by glomeruli, so increased urinary levels could reflect
increased serum levels or increased excretion from injured tubular cells [19]. In this regard,
uCypA could be an early AKI marker [19,46]. We now observed that uCypA increased in
clinical situations characterized by kidney IRI, such as renal artery clamping during IRI-NSS
and living donor IRI-KT. We took advantage of clinical situations in which urine output and
sCr may not represent kidney injury to characterize uCypA as a marker of AKI independent
from kidney function. Thus, in NSS, the combination of a healthy kidney and limited
ischemia usually results in stable sCr and diuresis, while in living donor transplantation,
any ischemia-induced kidney dysfunction is obscured by the fact that even when injured,
the kidney graft provides higher glomerular filtration than non-functioning native kidneys.
Both clinical situations displayed a similar uCypA time-course, characterized by a very
early increase (just after surgery was completed) and a progressive increase thereafter that
is consistent with our current understanding of cell death dynamics in AKI [6]. Thus, an
immediate wave of cell death in direct response to the insult may be followed by a second
wave of cell death at 48–72 h fueled by local inflammation and lethal cytokines produced in
response to the original insult and to the first wave of proinflammatory cell death, i.e., by
RN [3,6,45]. The more limited time-course of increased uCypA in NSS with arterial clamp
may represent the more limited nature of the insult, and, consequently, of kidney injury.
In this regard, the magnitude of the change was larger in KT patients that in NSS with
clamping (20.82 ± 6.8 vs. 10.58 ± 3.2 ng/mg at 48 h). The early post-transplant period is
characterized by very high urine creatinine excretion, as not only the ongoing production
of creatinine by muscle is excreted, but additionally the very high pre-transplant levels
of creatinine are excreted. Thus, the normalization of uCypA by urinary creatinine may
underestimate the magnitude of the change. In patients under renal replacement treatment
(hemodialysis and peritoneal dialysis) elevated plasma CypA levels have been linked with
systemic inflammation [43]. If, in the transplant situation, uCypA originated mainly from
the circulation, this would have resulted in higher initial uCypA levels and a progressive
reduction thereafter. However, in our KT population, uCypA increased progressively up to
48 to 72 h after KT, while kidneys had immediate function and sCr decreased after surgery.
This is again consistent with the second wave of cell death triggered by the initial insult
induction of proinflammatory RN cell death.
As increased uCypA has been observed in diabetic nephropathy. An interesting
question is whether pre-existing conditions are also associated with increased uCypA [17].
This is the case for putative markers of AKI, such as NGAL and KIM-1 [33], as we confirmed
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in the present report for NGAL. Indeed, this might also be the case for uCypA, although we
could not observe it. In any case, diabetic nephropathy is recognized to be associated with
an increased rate of cell death [18,47], thus supporting a potential association of uCypA
with tubular cell death.
The description of urinary markers of kidney injury that respond to NSS and KT
insults, even in the absence of clinical evidence of AKI, opens the door to quantification
of kidney injury in these scenarios and to future studies assessing the long-term outcome
impact on kidney function of different degrees of injury. Additionally, it will allow for the
assessment of the impact of different nephroprotective maneuvers aimed at decreasing
kidney injury during surgery or in the immediate post-surgery period.
Some limitations should be acknowledged. The sample size was relatively small,
and long-term outcomes were not evaluated. In this regard, the cut-off points used in
the present study represent working cut-off points that should be better defined in future
studies. Additionally, the study was not randomized. Thus, clamping was usually decided
based on surgical conditions and was usually performed in larger tumors, as evidenced by
larger tumor size and higher DAP and NePhRO nephrometry data. However, NSS and KT
data were consistent, and this information may guide the design of future observational or
interventional studies.
5. Conclusions
CypA is released by kidney tubular cells exposed to diverse lethal stimuli inducing
different forms of cell death, suggesting that it may clinically be useful in diverse conditions
associated with AKI. In this regard, increased uCypA levels were found in clinical situations
of IRI-induced kidney injury in which the functional impact of kidney injury could not
be reliably assessed, and provided information different from uNGAL, uCypA appearing
more sensitive to IRI (Figure 9). Thus, current AKI diagnosis requires a decreased kidney
function, resulting in increased sCr or decreased urinary output (Figure 9A). However, sCr
may increase for functional reasons, in the absence of kidney injury (Figure 9B). By contrast,
in unilateral IRI resulting from clamping of renal artery in NSS, the contralateral kidney
provides still enough kidney function to minimize changes in sCr despite injury to the
clamped kidney (Figure 9C). Under these conditions, we observed that uCypA was a more
sensitive marker of IRI-induced kidney injury than sCr or classical markers of injury, such
as NGAL. In NSS without clamping there is no IRI and no IRI-related changes in uCypA
(Figure 9D). In KT, due to the virtually inexistent kidney function at baseline, graft IRI is
associated with decreasing sCr levels, despite graft kidney injury, as injured kidneys still
have better function than native kidneys (Figure 9E). Again, uCypA provided evidence
of kidney injury despite decreasing sCr and non-informative uNGAL. Thus, uCypA is
a potential biomarker of kidney injury even in patients not meeting current diagnostic
criteria for AKI, that are based on functional impact.
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